Clinical Trial: Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT07510100) titled 'Eque-cel for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma' on March 10.

Brief Summary: This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Equecabtagene Autoleucel) in subjects with relapsed and refractory Multiple Myeloma.

Study Start Date: May 10

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Multiple Myeloma

Intervention: DRUG: Fully Human BCMA Chimeric Antigen Receptor Autologous T Cell Injection (Eque-cel)

Eque-cel consists of autologous T lymphocytes transduce...